These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37428428)

  • 1. Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis.
    Wees I; Hendren NS; Kaur G; Roth LR; Grodin JL
    Curr Heart Fail Rep; 2023 Oct; 20(5):350-357. PubMed ID: 37428428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.
    Perfetto F; Zampieri M; Fumagalli C; Allinovi M; Cappelli F
    Intern Emerg Med; 2022 Jun; 17(4):957-969. PubMed ID: 35325395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Castiglione V; Franzini M; Aimo A; Carecci A; Lombardi CM; Passino C; Rapezzi C; Emdin M; Vergaro G
    Eur J Heart Fail; 2021 Feb; 23(2):217-230. PubMed ID: 33527656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
    Barrett CD; Dobos K; Liedtke M; Tuzovic M; Haddad F; Kobayashi Y; Lafayette R; Fowler MB; Arai S; Schrier S; Witteles RM
    JACC Heart Fail; 2019 Nov; 7(11):958-966. PubMed ID: 31606365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
    Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
    Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
    Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
    Kastritis E; Papassotiriou I; Terpos E; Roussou M; Gavriatopoulou M; Komitopoulou A; Skevaki C; Eleutherakis-Papaiakovou E; Pamboucas C; Psimenou E; Manios E; Giannouli S; Politou M; Gakiopoulou H; Papadopoulou E; Stamatelopoulos K; Tasidou A; Dimopoulos MA
    Blood; 2016 Jul; 128(3):405-9. PubMed ID: 27166361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
    Perlini S; Mussinelli R; Salinaro F
    Curr Heart Fail Rep; 2016 Dec; 13(6):267-272. PubMed ID: 27900617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bad players in AL amyloidosis in the current era of treatment.
    Kreiniz N; Gertz MA
    Expert Rev Hematol; 2023 Jan; 16(1):33-49. PubMed ID: 36620914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
    Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
    J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac amyloidosis: evolving approach to diagnosis and management.
    Meier-Ewert HK; Sanchorawala V; Berk JL; Ruberg FL
    Curr Treat Options Cardiovasc Med; 2011 Dec; 13(6):528-42. PubMed ID: 21989745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history and therapy of AL cardiac amyloidosis.
    Grogan M; Dispenzieri A
    Heart Fail Rev; 2015 Mar; 20(2):155-62. PubMed ID: 25447844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future circulating biomarkers for cardiac amyloidosis.
    Luciani M; Troncone L; Monte FD
    Acta Pharmacol Sin; 2018 Jul; 39(7):1133-1141. PubMed ID: 29770800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
    Tuzovic M; Kobayashi Y; Wheeler M; Barrett C; Liedtke M; Lafayette R; Schrier S; Haddad F; Witteles R
    Am J Cardiol; 2017 Oct; 120(8):1381-1386. PubMed ID: 28844519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
    Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
    Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.